Welcome to our dedicated page for BLUE WATER VENTURES news (Ticker: BWVI), a resource for investors and traders seeking the latest updates and insights on BLUE WATER VENTURES stock.
Blue Water Ventures Inc., with the symbol BWVI, is on a mission to locate and recover historic sunken ships with valuable cargos that offer material, intellectual, and social rewards. Their commitment to responsible and cooperative exploration of the marine environment includes industry best practices, open dissemination of knowledge, transparency of intent, and international cooperation. This company provides updates on their projects, historic shipwreck recovery, financing expeditions, locating and preserving artifacts, and the tools and techniques involved.
In recent news, the company's novel NeuroDirect™ topical ketamine formulation for treating PTSD has shown positive results in Phase I trials. With a focus on safe and effective delivery of ketamine for mental health treatments, Blue Water Ventures Inc. is dedicated to developing cutting-edge technologies for the next generation of mental health therapies.
Psycheceutical Bioscience (OTC PINK:BWVI) is grappling with long-standing regulatory filing deficiencies that hinder its corporate actions, such as name and symbol changes, mergers, and reverse splits. These issues date back over a decade and remain a notable challenge. Despite the difficulties, the company is working with professionals to find a solution and aims to provide updates soon. Executive Chairman and CEO Neilank K. Jha emphasized their commitment to overcoming these challenges and restoring shareholder value.
Psycheceutical Bioscience (OTC: BWVI) is advancing its NeuroDirect™ ketamine topical cream aimed at treating PTSD. Recently, Rick Doblin, founder of MAPS, visited the company's lab to discuss the technology. The NeuroDirect delivery system promises to administer psychedelic compounds non-invasively, potentially minimizing side effects. Preliminary data show that 80% of patients in pre-clinical studies reported significant PTSD relief without psychoactive effects. The company is preparing to initiate clinical trials in Q2 2023. This innovation may improve treatment efficacy and reduce costs for patients.
Psycheceutical Bioscience (OTC: BWVI) announced a pre-clinical study published in Drug Development & Delivery revealing that over 80% of patients reported relief from PTSD symptoms within minutes of using NeuroDirect™ ketamine topical cream. The study highlights the cream's potential effectiveness over traditional systemic ketamine treatments, suggesting it could be more cost-effective. Patients noted improved focus and awareness without adverse psychogenic effects. The innovative delivery method aims to bypass side effects associated with psychedelic compounds, providing a safer, at-home treatment option for mental health disorders.
FAQ
What is the current stock price of BLUE WATER VENTURES (BWVI)?
What is the market cap of BLUE WATER VENTURES (BWVI)?
What is Blue Water Ventures Inc. known for?
What is the company's commitment to marine exploration?
What recent achievement has the company made in the field of mental health treatments?
What kind of technologies is the company focused on developing?
How does the company finance its expeditions and projects?
